Financial News

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) COVID-19 NanoAb Takes Centerstage at the 2023 BIO CEO & Investor Conference

  • Amir Reichman, BiondVax CEO, represented the company at this year’s BIO CEO & Investor Conference held at the Marriott Marquis, New York, on February 6-8
  • His presentation focused on the company’s recent successful pre-clinical in vivo results on its innovative inhaled COVID-19 treatment
  • Additional results from the study were release in January 2023, indicating that, compared to the control group, hamsters that received the drug one day after infection had negligible SARS-CoV-2 vital titers in their lungs and experienced a significantly milder and shorter illness
  • BiondVax’s management is optimistic that its self-administered inhaled NanoAbs will be highly attractive to at-risk people wishing to proactively, effectively, conveniently, and safely protect themselves

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products mainly for treating infectious and autoimmune diseases, took part in the 2023 BIO CEO & Investor Conference held at the Marriott Marquis, New York. The conference, which took place from February 6-8, offered a platform for stakeholders in the biotech industry, bringing together C-Suite leaders and the investor and banking communities for an opportunity to shape the future investment landscape in the biotechnology sector (https://ibn.fm/zLsni).

Amir Reichman, BiondVax’s CEO, represented the company, focusing his presentation on its recent highly successful pre-clinical in vivo results of its innovative inhaled COVID-19 treatment. He also touched on additional pipeline plans for BiondVax, including, but not limited to, nanosized…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback